Cover Image

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative allogeneic stem cell transplantation (Allo-SCT). Twenty-four of 63 patients (38.1%) responded: 12 patients (19.0%) with a partial response (PR) and...

Full description

Saved in:
Bibliographic Details
Main Authors: Donk, Niels van de (Author) , Kröger, N. (Author) , Hegenbart, Ute (Author) , Corradini, P. (Author) , Miguel, J. F. San (Author) , Goldschmidt, Hartmut (Author) , Perez-Simon, J. A. (Author) , Zijlmans, M. (Author) , Raymakers, R. A. (Author) , Montefusco, V. (Author) , Ayuk, F. A. (Author) , van Oers, M. H. J. (Author) , Nagler, A. (Author) , Verdonck, L. F. (Author) , Lokhorst, H. M. (Author)
Format: Article (Journal)
Language:English
Published: 07 June 2006
In: Bone marrow transplantation
Year: 2006, Volume: 37, Issue: 12, Pages: 1135-1141
ISSN:1476-5365
DOI:10.1038/sj.bmt.1705393
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bmt.1705393
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/1705393
Get full text
Author Notes:N. W. C. J. van de Donk, N. Kröger, U. Hegenbart, P. Corradini, J. F. San Miguel, H. Goldschmidt, J. A. Perez-Simon, M. Zijlmans, R. A. Raymakers, V. Montefusco, F. A. Ayuk, M. H. J. van Oers, A. Nagler and L. F. Verdonck, H. M. Lokhorst
Description
Summary:In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative allogeneic stem cell transplantation (Allo-SCT). Twenty-four of 63 patients (38.1%) responded: 12 patients (19.0%) with a partial response (PR) and 12 patients (19.0%) with a complete response (CR). Overall survival after donor lymphocyte infusions (DLI) was 23.6 months (1.0-50.7+). Median overall survival for non-responding patients was 23.6 months and has not been reached for the patients responding to DLI. In responders, progression-free survival after DLI was 27.8 months (1.2-46.2+). Patients with a PR had a median progression-free survival of 7.0 months, whereas patients with a CR to DLI had a median progression-free survival of 27.8 months. Major toxicities were acute graft-versus-host disease (GVHD) (38.1%) and chronic GVHD (42.9%). Seven patients (11.1%) died from treatment-related mortality. The only significant prognostic factors for response to DLI were the occurrence of acute and chronic GVHD. There was a trend towards significance for time between transplantation and DLI, and response. Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease.
Item Description:Gesehen am 15.02.2022
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/sj.bmt.1705393

Similar Items